Oluseyi Ojeifo1, Stephen D Wiviott2, Elliott M Antman2, Sabina A Murphy2, Jacob A Udell3, Eric R Bates4, Jessica L Mega2, Marc S Sabatine2, Michelle L O'Donoghue5. 1. Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. 2. TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts. 3. Division of Cardiology, Women's College Hospital, University of Toronto, Toronto, Ontario, Canada. 4. Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan. 5. TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts. Electronic address: modonoghue@partners.org.
Abstract
OBJECTIVES: This study sought to evaluate the clinical relevance of potential clopidogrel drug-drug interactions. BACKGROUND: Some studies have demonstrated that statins and calcium-channel blockers (CCBs) may attenuate the pharmacodynamic effects of clopidogrel. METHODS: The TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38) enrolled 13,608 patients with an acute coronary syndrome (ACS) and planned percutaneous coronary intervention (PCI), and randomized them to clopidogrel or prasugrel. Use of a statin or CCB was left to the discretion of the treating physician. A multivariable Cox model with propensity score was employed to evaluate the association between statin or CCB use and clinical outcomes. RESULTS: Of the 6,795 subjects assigned to clopidogrel, 4,794 (70.6%) were on a CYP3A4-metabolized statin, and 966 (14.2%) were on a CCB at randomization. The risk of cardiovascular (CV) death, myocardial infarction (MI), or stroke was similar regardless of baseline use of statins (adjusted hazard ratio [HR]: 1.02, 95% confidence interval [CI]: 0.85 to 1.22) or CCBs (adjusted HR: 1.16; 95% CI: 0.94 to 1.43) in clopidogrel-treated patients. Further, the combined use of a CCB and atorvastatin 80 mg daily (adjusted HR: 0.82; 95% CI: 0.37 to 1.84), or a CCB, statin, and proton pump inhibitor (adjusted HR: 1.04; 95% CI: 0.70 to 1.54) were not associated with an increased risk of CV death, MI, or stroke. The use of statins or CCBs did not modify the relative efficacy of prasugrel versus clopidogrel for the primary endpoint (p for interaction = 0.43, 0.55, respectively). CONCLUSIONS: In patients with ACS undergoing PCI, the use of statins or CCBs was not associated with an increased risk of CV events in clopidogrel-treated patients. Consistent results were observed when the drugs were administered alone, together, or in combination with proton pump inhibitors.
RCT Entities:
OBJECTIVES: This study sought to evaluate the clinical relevance of potential clopidogrel drug-drug interactions. BACKGROUND: Some studies have demonstrated that statins and calcium-channel blockers (CCBs) may attenuate the pharmacodynamic effects of clopidogrel. METHODS: The TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38) enrolled 13,608 patients with an acute coronary syndrome (ACS) and planned percutaneous coronary intervention (PCI), and randomized them to clopidogrel or prasugrel. Use of a statin or CCB was left to the discretion of the treating physician. A multivariable Cox model with propensity score was employed to evaluate the association between statin or CCB use and clinical outcomes. RESULTS: Of the 6,795 subjects assigned to clopidogrel, 4,794 (70.6%) were on a CYP3A4-metabolized statin, and 966 (14.2%) were on a CCB at randomization. The risk of cardiovascular (CV) death, myocardial infarction (MI), or stroke was similar regardless of baseline use of statins (adjusted hazard ratio [HR]: 1.02, 95% confidence interval [CI]: 0.85 to 1.22) or CCBs (adjusted HR: 1.16; 95% CI: 0.94 to 1.43) in clopidogrel-treated patients. Further, the combined use of a CCB and atorvastatin 80 mg daily (adjusted HR: 0.82; 95% CI: 0.37 to 1.84), or a CCB, statin, and proton pump inhibitor (adjusted HR: 1.04; 95% CI: 0.70 to 1.54) were not associated with an increased risk of CV death, MI, or stroke. The use of statins or CCBs did not modify the relative efficacy of prasugrel versus clopidogrel for the primary endpoint (p for interaction = 0.43, 0.55, respectively). CONCLUSIONS: In patients with ACS undergoing PCI, the use of statins or CCBs was not associated with an increased risk of CV events in clopidogrel-treated patients. Consistent results were observed when the drugs were administered alone, together, or in combination with proton pump inhibitors.
Authors: Anna Toso; Stefano De Servi; Mario Leoncini; Dominick J Angiolillo; Paolo Calabrò; Federico Piscione; Marco Cattaneo; Diego Maffeo; Antonio Bartorelli; Cataldo Palmieri; Marco De Carlo; Davide Capodanno; Philippe Genereux; Francesco Bellandi; Chiara Barozzi; Luciana Tomasi; Diego Della Riva; Tullio Palmerini Journal: J Thromb Thrombolysis Date: 2017-10 Impact factor: 2.300
Authors: Jin Sup Park; Kwang Soo Cha; Hye Won Lee; Jun-Hyok Oh; Jung Hyun Choi; Han Cheol Lee; Taek Jong Hong; Hyo Soo Kim Journal: Heart Vessels Date: 2016-11-30 Impact factor: 2.037
Authors: Patrizia Natale; Suetonia C Palmer; Valeria M Saglimbene; Marinella Ruospo; Mona Razavian; Jonathan C Craig; Meg J Jardine; Angela C Webster; Giovanni Fm Strippoli Journal: Cochrane Database Syst Rev Date: 2022-02-28
Authors: Rolf P Kreutz; Jeffrey A Breall; Anjan Sinha; Elisabeth von der Lohe; Richard J Kovacs; David A Flockhart Journal: Clin Pharmacol Date: 2016-06-03